Goetz MP, O'Shaughnessy J, Sledge Jr., et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. SABCS 2017, GS6-02.
Auto-immuunziekte geen contra-indicatie voor PD-(L)1-remmer
jul 2022 | Immuuntherapie